Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.

Ajit G. Thomas, Krystyna M. Wozniak, Takashi Tsukamoto, David Calvin, Ying Wu, Camilo Rojas, James Vornov, Barbara S. Slusher

Research output: Contribution to journalArticle

Abstract

GCP II inhibition decreases extracellular excitotoxic glutamate and increases extracellular NAAG, both of which provide neuroprotection. We have demonstrated with our potent and selective GCP II inhibitors efficacy in models of stroke, ALS and neuropathic pain. GCP II inhibition may have significant potential benefits over existing glutamate-based neuroprotection strategies. The upstream mechanism seems selective for excitotoxic induced glutamate release, as GCP II inhibitors in normal animals induced no change in basal glutamate. This suggestion has recently been corroborated by Lieberman and coworkers24 who found that both NAAG release and increase in GCP II activity appear to be induced by electrical stimulation in crayfish nerve fibers and that subsequent NAAG hydrolysis to glutamate contributes, at least in part, to subsequent NMDA receptor activation. Interestingly, even at relatively high doses of compounds, GCP II inhibition did not appear to be associated with learning/memory deficits in animals. Additionally, quantitative neurophysiological testing data and visual analog scales for 'psychedelic effects' in Phase I single dose and repeat dose studies showed GCP II inhibition to be safe and well tolerated by both healthy volunteers and diabetic patients. GCP II inhibition may represent a novel glutamate regulating strategy devoid of the side effects that have hampered the development of postsynaptic glutamate receptor antagonists.

Original languageEnglish (US)
JournalAdvances in Experimental Medicine and Biology
Volume576
StatePublished - 2006
Externally publishedYes

Fingerprint

Glutamate Carboxypeptidase II
Glutamic Acid
Animals
Therapeutics
Hallucinogens
Excitatory Amino Acid Antagonists
Astacoidea
Memory Disorders
Neuralgia
N-Methyl-D-Aspartate Receptors
Visual Analog Scale
Nerve Fibers
Electric Stimulation
Inhibition (Psychology)
Hydrolysis
Healthy Volunteers
Chemical activation
Stroke
Learning
Data storage equipment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. / Thomas, Ajit G.; Wozniak, Krystyna M.; Tsukamoto, Takashi; Calvin, David; Wu, Ying; Rojas, Camilo; Vornov, James; Slusher, Barbara S.

In: Advances in Experimental Medicine and Biology, Vol. 576, 2006.

Research output: Contribution to journalArticle

@article{3f8aa06803774365a899671113ff9e01,
title = "Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.",
abstract = "GCP II inhibition decreases extracellular excitotoxic glutamate and increases extracellular NAAG, both of which provide neuroprotection. We have demonstrated with our potent and selective GCP II inhibitors efficacy in models of stroke, ALS and neuropathic pain. GCP II inhibition may have significant potential benefits over existing glutamate-based neuroprotection strategies. The upstream mechanism seems selective for excitotoxic induced glutamate release, as GCP II inhibitors in normal animals induced no change in basal glutamate. This suggestion has recently been corroborated by Lieberman and coworkers24 who found that both NAAG release and increase in GCP II activity appear to be induced by electrical stimulation in crayfish nerve fibers and that subsequent NAAG hydrolysis to glutamate contributes, at least in part, to subsequent NMDA receptor activation. Interestingly, even at relatively high doses of compounds, GCP II inhibition did not appear to be associated with learning/memory deficits in animals. Additionally, quantitative neurophysiological testing data and visual analog scales for 'psychedelic effects' in Phase I single dose and repeat dose studies showed GCP II inhibition to be safe and well tolerated by both healthy volunteers and diabetic patients. GCP II inhibition may represent a novel glutamate regulating strategy devoid of the side effects that have hampered the development of postsynaptic glutamate receptor antagonists.",
author = "Thomas, {Ajit G.} and Wozniak, {Krystyna M.} and Takashi Tsukamoto and David Calvin and Ying Wu and Camilo Rojas and James Vornov and Slusher, {Barbara S.}",
year = "2006",
language = "English (US)",
volume = "576",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy.

AU - Thomas, Ajit G.

AU - Wozniak, Krystyna M.

AU - Tsukamoto, Takashi

AU - Calvin, David

AU - Wu, Ying

AU - Rojas, Camilo

AU - Vornov, James

AU - Slusher, Barbara S.

PY - 2006

Y1 - 2006

N2 - GCP II inhibition decreases extracellular excitotoxic glutamate and increases extracellular NAAG, both of which provide neuroprotection. We have demonstrated with our potent and selective GCP II inhibitors efficacy in models of stroke, ALS and neuropathic pain. GCP II inhibition may have significant potential benefits over existing glutamate-based neuroprotection strategies. The upstream mechanism seems selective for excitotoxic induced glutamate release, as GCP II inhibitors in normal animals induced no change in basal glutamate. This suggestion has recently been corroborated by Lieberman and coworkers24 who found that both NAAG release and increase in GCP II activity appear to be induced by electrical stimulation in crayfish nerve fibers and that subsequent NAAG hydrolysis to glutamate contributes, at least in part, to subsequent NMDA receptor activation. Interestingly, even at relatively high doses of compounds, GCP II inhibition did not appear to be associated with learning/memory deficits in animals. Additionally, quantitative neurophysiological testing data and visual analog scales for 'psychedelic effects' in Phase I single dose and repeat dose studies showed GCP II inhibition to be safe and well tolerated by both healthy volunteers and diabetic patients. GCP II inhibition may represent a novel glutamate regulating strategy devoid of the side effects that have hampered the development of postsynaptic glutamate receptor antagonists.

AB - GCP II inhibition decreases extracellular excitotoxic glutamate and increases extracellular NAAG, both of which provide neuroprotection. We have demonstrated with our potent and selective GCP II inhibitors efficacy in models of stroke, ALS and neuropathic pain. GCP II inhibition may have significant potential benefits over existing glutamate-based neuroprotection strategies. The upstream mechanism seems selective for excitotoxic induced glutamate release, as GCP II inhibitors in normal animals induced no change in basal glutamate. This suggestion has recently been corroborated by Lieberman and coworkers24 who found that both NAAG release and increase in GCP II activity appear to be induced by electrical stimulation in crayfish nerve fibers and that subsequent NAAG hydrolysis to glutamate contributes, at least in part, to subsequent NMDA receptor activation. Interestingly, even at relatively high doses of compounds, GCP II inhibition did not appear to be associated with learning/memory deficits in animals. Additionally, quantitative neurophysiological testing data and visual analog scales for 'psychedelic effects' in Phase I single dose and repeat dose studies showed GCP II inhibition to be safe and well tolerated by both healthy volunteers and diabetic patients. GCP II inhibition may represent a novel glutamate regulating strategy devoid of the side effects that have hampered the development of postsynaptic glutamate receptor antagonists.

UR - http://www.scopus.com/inward/record.url?scp=33747410569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747410569&partnerID=8YFLogxK

M3 - Article

C2 - 16802724

VL - 576

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -